Page 61 - Read Online

Constantinides et al. Neuroimmunol Neuroinflammation 2020;7:120-31 I http://dx.doi.org/10.20517/2347-8659.2019.22 Page 129

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study
of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
3. Trojanowski JQ, Revesz T; Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis
of multiple system atrophy. Neuropathol Appl Neurobiol 2007;33:615-20.
4. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, et al. Consensus guidelines for the clinical and pathologic diagnosis of
dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
5. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-
Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-9.
6. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, et al. Office of rare diseases neuropathologic criteria for corticobasal
degeneration. J Neuropathol Exp Neurol 2002;61:935-46.
7. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau:
sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 1989;3:519-26.
8. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. The diagnosis of dementia due to Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s
disease. Alzheimers Dement 2011;7:263-9.
9. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. NIA-AA Research Framework: Toward a biological definition of
Alzheimer’s disease. Alzheimers Dement 2018;14:535-62.
10. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in
Parkinson’s disease and progressive supranuclear palsy. Mov Disord 2003;18:186-90.
11. Verbeek MM, Abdo WF, De Jong D, Horstink MW, Kremer BP, et al. Cerebrospinal fluid Abeta42 levels in multiple system atrophy. Mov
Disord 2004;19:238-40.
12. Aerts MB, Esselink RA, Bloem BR, Verbeek MM. Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal
syndrome. Mov Disord 2011;26:169-73.
13. Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the
differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-52.
14. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, et al. Cerebrospinal fluid markers for differential dementia
diagnosis in a large memory clinic cohort. Neurology 2012;78:47-54.
15. Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, et al. A panel of nine cerebrospinal fluid biomarkers may identify
patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015;86:1240-7.
16. Constantinides VC, Paraskevas GP, Emmanouilidou E, Petropoulou O, Bougea A, et al. CSF biomarkers beta-amyloid, tau proteins and
a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J Neurol Sci 2017;382:91-5.
17. Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with
progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2005;237:61-5.
18. Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, et al. Divergent CSF tau alterations in two common tauopathies: Alzheimer’s
disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2015;86:244-50.
19. Schirinzi T, Sancesario GM, Di Lazzaro G, Scalise S, Colona VL, et al. Clinical value of CSF amyloid-beta-42 and tau proteins in
Progressive Supranuclear Palsy. J Neural Transm (Vienna) 2018;125:1373-9.
20. Süssmuth SD, Uttner I, Landwehrmeyer B, Pinkhardt EH, Brettschneider J, et al. Differential pattern of brain-specific CSF proteins tau
and amyloid-beta in Parkinsonian syndromes. Mov Disord 2010;25:1284-8.
21. Mitani K, Furiya Y, Uchihara T, Ishii K, Yamanouchi H, et al. Increased CSF tau protein in corticobasal degeneration. J Neurol
1998;245:44-6.
22. Urakami K, Mori M, Wada K, Kowa H, Takeshima T, et al. A comparison of tau protein in cerebrospinal fluid between corticobasal
degeneration and progressive supranuclear palsy. Neurosci Lett 1999;259:127-9.